1	Higher ratio of plasma omega-6/omega-3 fatty acids is associated
2	with greater risk of all-cause, cancer, and cardiovascular mortality:
3	a population-based cohort study in UK Biobank
4	
5	Authors: Yuchen Zhang, MSPH ¹ ; Yitang Sun, MPH ² ; Qi Yu, MSPH ³ , Suhang Song, PhD ⁴ , J.
6	Thomas Brenna, PhD ^{5,6} ; Ye Shen, PhD ^{1*} ; Kaixiong Ye, PhD ^{2,7*}
7	
8	Author Affiliations:
9	¹ Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia,
10	Athens, Georgia, US
11	² Department of Genetics, University of Georgia, Athens, Georgia, US
12	³ Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, US
13	⁴ Department of Health Policy and Management, College of Public Health, University of Georgia,
14	Athens, Georgia, US
15	⁵ Division of Nutritional Sciences, Cornell University, Ithaca, NY, US
16	⁶ Dell Pediatric Research Institute and the Depts of Pediatrics, of Nutrition, and of Chemistry,
17	University of Texas at Austin, Austin, TX, US
18	⁷ Institute of Bioinformatics, University of Georgia, Athens, Georgia, US
19	* YS and KY jointly supervised this project.
20	
21	Corresponding Author:
22	Kaixiong Ye, PhD
23	Department of Genetics, C220 Davison Life Sciences Complex, University of Georgia, 120 East
24	Green Street, Athens, GA 30602
25	Phone: 706-542-5898 Email: kaixiong.ye@uga.edu
26	Ye Shen, PhD
27	Department of Epidemiology and Biostatistics, University of Georgia, 101 Buck Rd, Athens, GA
28	30602
29	Phone: 706-542-2754 Email: yeshen@uga.edu

30 Abstract

31 Background

32 Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated

33 with various chronic diseases and mortality, but results are conflicting. Few studies examined the

- 34 role of omega-6/omega-3 ratio in mortality.
- 35

36 Methods

37 We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and

38 cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants

39 who had complete information on circulating PUFAs, 6,461 died during follow-up, including

40 2,794 from cancer and 1,668 from cardiovascular disease (CVD). Associations were estimated

- 41 by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.
- 42

43 **Results**

- 44 Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs
- 45 increased (all $P_{trend} < 0.05$). Comparing the highest to the lowest quintiles, individuals had 26%

46 (95% CI, 15-38%) higher total mortality, 14% (95% CI, 0-31%) higher cancer mortality, and 31%

47 (95% CI, 10-55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma

were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showingstronger effects.

50

51 **Conclusions**

Using a population-based cohort in UK Biobank, our study revealed a strong association between
the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD
mortality.

55

56 Keywords

57 Polyunsaturated fatty acids, Omega-3 fatty acids, Omega-6 fatty acids, Mortality, Prospective
58 studies

59

60 Background

61

Cancer and cardiovascular disease (CVD) are the two leading causes of non-communicable 62 63 disease mortality globally¹. Substantial epidemiologic evidence has linked the dietary or circulating levels of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) to the risks of 64 65 all-cause, cancer, and CVD mortality (Additional file 1: Table S1). However, the results are inconsistent, especially for omega-6 PUFAs. Most large observational studies support the inverse 66 67 associations between omega-3 PUFAs and mortality. In addition to total and individual omega-3 68 PUFAs, the omega-3 index, defined as the percentage of eicosapentaenoic acid (EPA) and 69 docosahexaenoic acid (DHA) in total fatty acids in red blood cells, was shown to be a validated 70 biomarker of the dietary intake and tissue levels of long-chain omega-3 PUFAs, and was proposed to be a risk factor for CVD and related mortality^{2,3}. While the omega-3 index has been 71 72 observed to be inversely associated with all cause-mortality, its association patterns with CVD and cancer mortality are less clear⁴⁻⁶. Most importantly, results from clinical trials of omega-3 73 PUFA supplementation have been inconsistent^{7,8}. On the other hand, while some studies revealed 74 inverse associations of omega-6 PUFAs with all-cause mortality⁹⁻¹¹, others reported null 75 results^{4,12-15}. The role of omega-6 PUFAs in cancer and CVD mortality is less studied, and the 76 patterns are similarly conflicting^{4,9-11}. Interpreting previous observational results is challenging 77 due to the limitations of small sample sizes, insufficient adjustments for confounding, and unique 78 sample characteristics. Moreover, many studies rely on self-reported dietary intake or fish oil 79 supplementation status, which are subject to large variability and reporting bias¹⁶. Despite the 80 81 tremendous interest and research effort, the roles of omega-3 and omega-6 PUFAs in all-cause 82 and cause-specific mortality remain uncertain.

83

84 It has been suggested that the high omega-6/omega-3 ratio in Western diets, 20:1 or even higher, 85 as compared to an estimated 1:1 during the most time of human evolution, contributes to many chronic diseases, including CVD, cancer, and autoimmune disorders^{17,18}. However, while many 86 87 previous studies have examined total or individual omega-3 and omega-6 PUFAs, fewer 88 investigated the role of their imbalance, as measured by the omega-6/omega-3 ratio, in mortality^{4,14,15,19}. In a prospective cohort study of postmenopausal women, the omega-6/omega-3 89 90 ratio in red blood cells was associated with an increased risk of all-cause mortality but not with cancer or CVD mortality⁴. Similar positive associations with all-cause mortality were observed 91 in smaller cohorts investigating the ratio in serum or dietary intake^{14,19}. However, prospective 92 93 studies in two independent cohorts from China and US did not find a linear positive association between the omega-6/omega-3 ratio in diet and all-cause mortality¹⁵. To address these gaps in 94 our understanding of the roles of omega-3 and omega-6 PUFAs and their imbalance in all-cause 95 96 and cause-specific mortality, we perform a prospective study in a large population-based cohort 97 (N = 85,425) from UK Biobank, using objective measurements of PUFA levels in plasma.

98

99 Methods

100 Study population

101 The UK Biobank study is a prospective, population-based cohort study in the United Kingdom²⁰. 102 Between 2006 and 2010, 502,384 prospective participants, aged 40-69, in 22 assessment Centers 103 throughout the UK were recruited for the study. The population information was collected 104 through a self-completed touch-screen questionnaire; brief computer-assistant interview; 105 physical and functional measures; and blood, urine, and saliva collection during the assessment 106 visit. Participants with cancer (n=37,736) or CVD (n=100,972), those who withdrew from the

study (n=879), and those with incomplete data on the plasma omega-6/omega-3 ratio (n=277,372)
were excluded from this study, leaving 85,425 participants, 6,461 died during follow-up,
including 2,794 from cancer and 1,668 from CVD.

110

111 Ascertainment of exposure

112 Metabolomic profiling of plasma samples was performed with high-throughput nuclear magnetic 113 resonance (NMR) spectroscopy. At the time of this analysis (15 Mar 2023), UK Biobank 114 released the Phase 1 metabolomic dataset, which covered a random selection of 118,461 plasma 115 samples from the baseline recruitment. These samples were collected between 2007 and 2010 116 and had been stored in -80 °C freezers, while the NMR measurements took place between 2019 117 and 2020. Detailed descriptions can be found in previous publications about plasma sample 118 preparation, NMR spectroscopy setup, quality control protocols, correction for sample dilution, 119 verification with duplicate samples and internal controls, and comparisons with independent measurements from clinical chemistry assays²⁰⁻²². Five PUFAs-related biomarkers were directly 120 121 measured in absolute concentration units (mmol/L), including total PUFAs, total omega-3 122 PUFAs, total omega-6 PUFAs, docosahexaenoic acid (DHA), and linoleic acid (LA). Of note, DHA is one type of omega-3 PUFAs, and LA is one type of omega-6 PUFAs. Our primary 123 124 exposure of interest, the omega-6/omega-3 ratio, was calculated based on their absolute 125 concentrations. We also performed supplemental analysis for four exposures, the percentages of 126 omega-3 PUFAs, omega-6 PUFAs, DHA, and LA in total fatty acids (omega-3%, omega-6%, 127 DHA%, and LA%), which were calculated by dividing their absolute concentrations to that of 128 total fatty acids.

129 Ascertainment of outcome

130 The date and cause of death were identified through the death registries of the National Health 131 Service (NHS) Information Centre for participants from England and Wales and the NHS Centre Register Scotland for participants from Scotland²⁰. At the time of the analysis (15 Mar 2023), we 132 133 had access to the most up-to-date mortality dataset (Version: December 2022), which had the 134 date of death up to 12 November 2021. Therefore, follow-up time was calculated as the time 135 between the date of entering the assessment centre and this date, or the date of death, whichever 136 happened first. The underlying cause of death was assigned and coded in vital registries according to the International Classification of Diseases, 10th revision (ICD-10). CVD mortality 137 138 was defined using codes I00-I99, and cancer mortality was defined using codes C00-D48. To 139 exclude those who had cancer at baseline, we used the overall cancer incidence information 140 based on diagnoses in cancer registers derived from the Health and Social Care Information Centre and the NHS Central Register that were coded based on ICD-9 and ICD-10 codes. The 141 142 information about CVD incidence was retrieved from Hospital inpatient data and Death Register 143 records that were coded according to ICD-9 and ICD-10 codes, and self-reported medical 144 condition.

145

146 Ascertainment of covariates

The baseline questionnaire included detailed information on several possible confounding variables: demographic factors (age, sex, assessment centre, ethnicity), socioeconomic status (Townsend Deprivation Index), lifestyle habits (alcohol assumption, smoking status, body mass index (BMI), physical activity, comorbidities (including hypertension, diabetes, and longstanding illness)), and other supplementation (Fish-oil supplementation). The Townsend Deprivation Index, used as an indicator of socioeconomic status, is retrieved directly from the

153 UK Biobank. BMI was defined as the body mass divided by the square of the body height and 154 was expressed in units of kg/m^2 . Comorbidities, including hypertension, diabetes, and 155 longstanding illness, were self-reported at baseline. Longstanding illness refers to any long-156 standing illness, disability, or infirmity, without other specific information. We also retrieved the 157 information on dietary PUFA intakes and serum biomarkers for secondary analysis. Dietary PUFAs were estimated based on the 24-hour dietary recall²³. The percentage of dietary omega-3 158 159 and omega-6 PUFA were calculated as the corresponding absolute dietary PUFA divided by 160 summation of dietary monounsaturated fatty acids, saturated fatty acids, omega-3 fatty acids, and 161 omega-6 fatty acids. The biochemistry markers were measured in the blood sample collected at 162 recruitment.

163

164 *Statistical analysis*

165 We summarized and compared the characteristics of the participants across quintiles of the 166 omega-6/omega-3 ratio at baseline using descriptive statistics. Pearson's Chi-squared test and 167 ANOVA test were used to compare the demographic characteristics across quintiles, respectively, 168 for categorical variables and continuous variables. To investigate associations of the ratio with 169 all-cause and cause-specific mortality, we used multivariable Cox proportional hazards regression models to calculate hazard ratios²⁴ and their 95% confidence intervals (CI). The 170 171 proportional hazards assumption was not violated based on Schoenfeld residuals. We analyzed 172 the ratio as continuous and categorical variables (i.e., quintiles). For all trend tests, we used the 173 median value of each quintile as a continuous variable in the models. Potential nonlinear 174 associations were assessed semi-parametrically using restricted cubic splines (4 knots were used in regression splines) 25 . 175

176

Based on previous literature and biological plausibility^{11,26,27}, we chose the following variables
as covariates in the multivariate models: age (years; continuous), sex (male, female), race (White,
Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI
(kg/m2; continuous), smoking status (never, previous, current), alcohol intake status (never,
previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

182

183 In secondary analyses to assess potential differences in associations across different population 184 subgroups, we repeated the above-described analyses stratified by age ($< vs. \ge$ the median age of 185 58 years), sex (male/female), Townsend deprivation index (< vs. \geq the population median of -2), 186 BMI (($\langle vs. \geq 25$), comorbidities (yes vs. no), physical activity (low and moderate vs. high) and 187 current smoking status (yes vs. no). Besides, to compare the effects of dietary intake of PUFAs 188 with the plasma levels on mortality, we repeated the above-described analyses in participants 189 with complete information on dietary intake PUFAs (N=153,064). Moreover, we conducted 190 mediation analysis to investigate potential biological pathways that might explain the effects of 191 omega-6/omega-3 ratio on mortality outcomes. Based on plausibility, we chose CRP as a 192 potential mediating factor for CVD mortality; SHBG, TTST, E2 and IGF-1 as potential 193 mediating factors for cancer mortality; and all the above biomarkers for all-cause mortality. We 194 first examined the variations in the concentrations of each biomarker according to omega-195 6/omega-3 ratio quintiles. Then we constructed two regression models, a linear model, to regress 196 the mediator (treated the biomarkers as continuous) on the exposure (treated the omega-6/omega-197 3 ratio as continuous), with fully-adjustment for potential confounders; and a Cox proportional 198 hazard model, to regress the outcome (mortality outcomes) on the exposure and the mediator,

with fully-adjustment for potential confounders. We chose to construct Cox models for mediation analysis because our outcomes were rare (all <10%)²⁸. We integrated these two regression models to obtain the indirect effects and proportions of mediating effects through the counterfactual-based approach proposed by Vander Weele^{29,30}.

203

204 We also conducted several sensitivity analyses. First, to assess whether the associations of the 205 omega-6/omega-3 ratio with mortality outcomes were primarily driven by omega-3 fatty acids or 206 omega-6 fatty acids, we assessed both the separate and the joint associations of omega-3 fatty 207 acids to total fatty acids percentage (omega-3%) and omega-6 fatty acids to total fatty acids 208 percentage (omega-6%) with the three mortality outcomes. We also performed a joint analysis 209 with categories of the omega-3% and omega-6% quintiles, using participants in both the lowest 210 omega-3% and omega-6% quintiles as the reference category. An interaction term between 211 omega-3% and omega-6% was included in the multivariable Cox proportional hazards model, 212 and a Likelihood Ratio test was used to assess its significance. The correlation between omega-3% 213 and omega-6% was assessed by the Pearson correlation. Second, to assess the effects of 214 individual PUFAs on mortality, we conducted the same analysis for circulating docosahexaenoic 215 acid to total fatty acids percentage (DHA%) and linoleic acid to total fatty acids percentage 216 (LA%) with the three mortality outcomes. Third, to address the potential residual confounding 217 by fish oil supplementation, we further adjusted for the supplementation status from the baseline 218 questionnaire. Fourth, to investigate the effects of missing values, we imputed missing values 219 (<1% for most factors, up to 19% for physical activity) by chained equations and performed synthesis analyses on the imputed datasets³¹. Fifth, to assess whether the observed associations 220 221 are attenuated by reverse causation, we excluded those who died in the first year of follow-up.

Last, to assess the representativeness of the participants included in our study, we compared the baseline characteristics between the participants with and without exposure information. All Pvalues were two-sided. We considered a P-value <0.05 or a 95% confidence interval (CI) excluding 1.0 for HRs as statistically significant. We conducted all analyses using R, version 4.0.3 and SAS statistical software, version 9.4 (SAS Institute Inc.).

227

228 **Results**

229 Baseline characteristics

In the analytic cohort of 85,425 participants, over a mean of 12.7 years of follow-up, 6,461 died, including 2,794 from cancer and 1,668 from CVD. The baseline characteristics of the participants across quintiles of the ratio of omega-6/omega-3 were summarized in **Table 1**. Study participants were, on average, 56 years old and 90% White. Those in the higher ratio quintiles were more likely to be younger, male, and current smokers, but less likely to have comorbidities and take fish oil supplementation.

236

237 Main results

The associations of the omega-6/omega-3 ratio with all-cause and cause-specific mortality risks were presented in **Table 2**. A higher ratio was strongly associated with higher mortality from all causes, cancer, and CVD ($P_{trend} < 0.05$ for all three). In the fully adjusted models that considered the ratio as a continuous variable, every unit increase in the ratio corresponded to 2%, 1%, and 2% higher risk in all-cause, cancer, and CVD mortality, respectively. When comparisons were made between the highest and the lowest quintile of the omega-6/omega-3 ratio, there were 26%, 14%, and 31% increased risk for all-cause, cancer, and CVD mortality, respectively.

245

246 Stratified analysis

247 The fully adjusted associations of the omega-6/omega-3 ratio with all-cause mortality revealed 248 that compared to the lowest quintile, the highest quintile has strong, statistically significant 249 associations with elevated risk within all categories of age, sex, TDI, BMI, comorbidities, 250 physical activity, and smoking status (Figure 1, Additional file 2: Table S2), except in those 251 aged less than 58 years old and BMI less than 25. The estimated associations with all-cause 252 mortality were stronger in current smokers (P for interaction < 0.01; Figure 1, Additional file 2: 253 Table S2). For cancer and CVD mortality, they also tended to be stronger among current 254 smokers but did not reach statistical significance (P for interaction = 0.13 and 0.12, respectively). 255 The associations with CVD mortality tended to be stronger among participants without 256 comorbidities (P for interaction <0.01). No significant interactions were found for other risk 257 factors (Figure 2).

258

259 Restricted cubic spline analysis

Restricted cubic spline analysis suggested significant positive associations of the omega-6/omega-3 ratio with all-cause, cancer, and CVD mortality (P < 0.05 for all three outcomes, **Figure 3**). Potential nonlinearity in these positive associations was identified for all-cause mortality (P < 0.05) and CVD mortality (P < 0.05) but not for cancer mortality (P = 0.12). The strength of the relationship between the ratio and all-cause mortality appears to remain at a relatively low level before it starts to increase quickly after the ratio exceeds 8. A similar trend with higher uncertainties was observed for CVD mortality.

267

268 Omega-3, Omega-6, Joint analysis, and comparison with dietary PUFAs

269 We further performed analyses to assess whether the associations of the omega-6/omega-3 ratio 270 with mortality outcomes were primarily driven by omega-3 or omega-6 fatty acids. The 271 correlation between omega-3% and omega-6% was relatively low with r = -0.12 (P < 0.01). 272 Across all models, both the omega-3% and omega-6% were inversely associated with all three 273 mortality outcomes, except for plasma omega-6% with CVD mortality under Model 3 ($P_{trend} <$ 274 0.01, Additional file 2: Table S3 and Table S4). Notably, their associations remained 275 significant when they were included in the same models. On the other hand, the effect sizes of 276 the inverse associations were always bigger for the omega-3% under the fully adjusted Model 3. 277 For example, when comparing those in the highest omega-3% quintile to the lowest quintile, the 278 fully adjusted HRs (95% CI) for all-cause, cancer, and CVD mortality were, respectively, 0.69 279 (0.63, 0.76), 0.75 (0.65, 0.87), and 0.68 (0.57, 0.82) (Additional file 2: Table S3). The 280 corresponding HRs for the omega-6% were 0.77 (0.70, 0.85), 0.80 (0.68, 0.92), and 0.83 (0.68, 281 1.02) (Additional file 2: Table S4). Furthermore, in another joint analysis of the omega-3% and 282 omega-6%, the lowest risk for all-cause and cancer mortality was observed among those in the 283 joint highest categories of the two fatty acids (Additional file 2: Table S5). For example, when 284 comparing those in the highest quintiles of the two fatty acids to the group with the joint lowest 285 group, the HRs (95% CI) for all-cause and cancer mortality were, respectively, 0.48 (95% CI, 286 0.35, 0.67) and 0.53 (95% CI, 0.33, 0.86). In the analysis of dietary PUFAs with mortality, the 287 effect sizes were smaller and less significant compared with those of the corresponding plasma 288 levels. When analyzed as continuous variables, dietary omega-3%, omega-6% and omega-289 6/omega-3 ratio were all significantly associated with all-cause, cancer, and CVD mortality, in 290 directions consistent with their plasma counterparts. The trend test across the five quintiles

revealed significant associations between dietary omega-3% and omega-6/omega-3 ratio with cancer mortality (P for trend<0.001 and =0.002, respectively; **Additional file 2: Table S6**). The correlation between dietary omega-3% and omega-6% was r = 0.41 (P < 0.01).

294

295 Mediation analysis for intermediate biomarkers

296 The baseline serum biomarkers of the participants across quintiles of the ratio of omega-297 6/omega-3 were summarized in Additional file 2: Table S7. The estimates for the three paths a 298 (association between plasma omega-6/omega-3 ratio and biomarkers), b (association between 299 biomarkers and mortality outcomes), and c (association between plasma omega-6/omega-3 ratio 300 and mortality outcomes), as well as the percentage of indirect effect (a to b) among the overall 301 associations, were reported in Additional file 2: Table S8 and Figure S1. These analyses 302 identified CRP and SHBG as potential mediators for the association of plasma omega-6/omega-3 303 ratio with all-cause mortality (proportion of mediating = 4% and 5.0%, respectively).

304 Other sensitivity analyses

305 We performed analyses to examine the associations of DHA% and LA% with mortalities. The 306 correlation between DHA% and LA% was relatively low with r = 0.03 (P < 0.01). Under the 307 fully-adjusted model, both DHA% and LA% were inversely associated with all three mortality 308 outcomes, regardless of treated as continuous or quintiles (Additional file 2: Table S9). After 309 further adjustment of the fish oil supplementation status, the associations between the ratio of 310 omega-6/omega-3 and mortality outcomes were slightly attenuated yet did not alter the main 311 findings (Additional file 2: Table S10). Our primary analysis excluded participants with 312 missing information (i.e., a complete-case analysis). We performed a sensitivity analysis using 313 the multiply-imputed datasets, and there were no substantial changes (Additional file 2: Table

S11). Moreover, the exclusion of participants who died during their first-year follow-up did not
materially alter the results (Additional file 2: Table S12). The baseline characteristics are
comparable between participants with or without exposure information (Additional file 2: Table
S13).

318

319 **Discussion**

320 In this prospective population-based study of UK individuals, we showed that a higher ratio of 321 plasma omega-6/omega-3 fatty acids was positively associated with the risk of all-cause, cancer, 322 and CVD mortality. These associations were independent of most risk factors examined, 323 including age, sex, TDI, BMI, comorbidities, and physical activity, but they were stronger in 324 current smokers. These relationships were linear for cancer mortality but not for all-cause and 325 CVD mortality. For those two outcomes, the risk of mortality first decreased at lower ratios and 326 then increased, with an inflection point around the ratio of 8. Moreover, omega-3 and omega-6 327 PUFAs in plasma were consistently and inversely associated with all-cause, cancer, and CVD 328 mortality, with omega-3 showing stronger effects.

329

To date, studies that examined the relationship between the ratio of omega-6/omega-3 PUFAs and mortality in the general population are sparse^{4,14,15,19}. Similar to our finding, in a 2017 report from a prospective women cohort study (n=6,501; 1,875 all-cause deaths, 617 CVD deaths, 462 cancer deaths)⁴, the adjusted HR for all-cause mortality was 1.10 (1.02-1.19) per 1-SD increase of omega-6/omega-3 ratio in red blood cells, however, the effects were not significant for cancer and CVD deaths. Another study supporting our results was conducted on elderly Japanese individuals (n=1,054; 422 deaths). It found that the ratio of an omega-3 fatty acid,

337 eicosapentaenoic acid, to an omega-6 fatty acid, arachidonic acid (ARA), is inversely associated 338 with all-cause mortality, with an HR of 0.71 (95% 0.53-0.96) comparing the highest to the lowest tertile¹⁴. Findings of previous studies based on dietary intake were null^{15,19}. A prospective 339 340 cohort involving 145 hemodialysis patients enrolled in Southern California during 2001-2007 341 (42 all-cause deaths) showed that the estimated HR (95% CI) for all-cause mortality among those 342 in the lowest relative to the highest quartiles of dietary omega-6/omega-3 ratio was 0.37 (0.14- $(1.08)^{19}$. Although the effect was not significant, it still shows the protective trend of a lower 343 344 omega-6/omega-3 ratio against premature death, when taking the sample size and study 345 population into consideration. In a 2019 report based on two population-based prospective 346 cohorts in China (n=14,117, 1,007 all-cause deaths) and the US (n=36,032, 4,826 all-cause 347 deaths), the effect of the omega-6/omega-3 ratio intake was not significant (HR (95% CI) is 0.95 (0.80-1.14) for China and 0.99 (0.89-1.11) for US, respectively)¹⁵. These discrepancies may be 348 349 explained by the usage of circulating biomarkers or dietary intakes for calculating the omega-350 6/omega-3 ratio. Indeed, we performed the same association analyses for dietary PUFAs and 351 found that their associations with mortality have smaller effect sizes and are less statistically 352 significant, although maintaining the same effect directions as plasma PUFAs. The estimated dietary intakes may be inaccurate due to recall bias or outdated food databases¹⁶. The circulating 353 354 level is a more objective measurement of PUFA status and thus provides a more reliable picture 355 of the effects of omega-3 and omega-6 PUFAs on mortality. Additionally, we observed that the 356 omega-6/omega-3 ratio tends to have stronger effects on mortality outcomes in current smokers. 357 This is consistent with a previous observation that the association between habitual fish oil supplementation and a lower risk of all-cause mortality is stronger in current smokers²⁶. 358 359 Moreover, we found that current smokers in UK Biobank tend to have higher omega-6/omega-3

360 ratios. Similarly, prior studies reported that current smokers have lower circulating omega-3 361 PUFAs than non-smokers but similar circulating levels of omega-6 PUFAs^{32,33}. It is likely that 362 omega-3 PUFAs play more important roles in current smokers, resulting in a stronger effect of 363 the omega-6/omega-3 ratio on mortality. However, the underlying mechanism awaits future 364 investigations.

365

366 A large number of existing observational studies documented the inverse association of circulating levels and intake of omega-3 PUFAs with mortality^{5,6,27,34-39}, which is in line with our 367 finding that individuals in the highest quintile of the plasma omega-3% had approximately 30% 368 369 lower risk for all-cause and CVD mortality and 25% lower risk for cancer mortality, when 370 compared to those in the lowest quintile. Our analysis of dietary omega-3% also revealed inverse 371 associations with all-cause and cancer mortality, with 9% and 18% lower risk, respectively. Few previous studies have examined the association in generally healthy populations^{5,27,34,36}. In a 372 2016 meta-analysis³⁴ of seven epidemiologic studies for dietary omega-3 PUFAs intake and four 373 374 studies for circulating levels, the estimated relative risk for all-cause mortality was 0.91 (95% CI: 375 0.84-0.98) when comparing the highest to the lowest categories of omega-3 PUFA intake. In two 376 2018 reports of population-based studies in the US, the circulating level and dietary intake of omega-3 PUFAs were significantly associated with lower total mortality^{5,27}. In a 2021 meta-377 378 analysis of 17 epidemiologic studies, comparing the highest to the lowest quintiles of circulating 379 EPA and DHA, the estimated HRs for all-cause, CVD, and cancer mortality were 0.84 (0.79-(0.89), (0.73-0.88) and (0.87) ((0.78-0.96), respectively³⁶. Moreover, inverse associations of 380 381 omega-3 PUFAs biomarkers with total mortality were found in patients with myocardial infarction^{37,39}, type 2 diabetes¹², and other diseases^{6,35,38,40}; inverse associations of omega-3 382

PUFAs with CVD mortality were also reported in these patient groups^{6,12,39}. However, there are also reports of a null relationship between omega-3 PUFAs and mortality^{13,14,41}. One possible explanation for the discrepancies could be the limited statistical power due to the small sample size and the small number of events. Moreover, the inconsistency may be due to unique sample characteristics; one study only involved elder patients¹⁴, and one only involved women⁴¹.

388

389 A smaller number of studies have evaluated the associations of omega-6 PUFAs with mortality. 390 Our findings in the large UK prospective cohort are in accordance with the results of several 391 previous studies that increased circulating levels of omega-6 PUFAs were associated with decreased all-cause mortality^{9,11,15,42}. Moreover, a 2019 meta-analysis involving 18 cohort 392 393 studies and 12 case-control studies showed that an omega-6 PUFA, linoleic acid, was inversely associated with CVD mortality; the HR per interquintile range was 0.78 (95% CI, 0.70-0.85)¹⁰. 394 Other studies, however, did not support such inverse associations^{4,12-14,41}. Although the findings 395 396 were inconsistent, no previous studies reported harmful effects of omega-6 PUFAs on mortality^{4,11-15,41-44}. Our studies support the inverse associations between omega-6 PUFAs and 397 398 all-cause and cause-specific mortality. Further research is needed to investigate the health 399 impacts of omega-6 PUFAs in laboratory studies, epidemiological investigations, and clinical 400 trials.

401

We observed that the omega-6/omega-3 ratio is positively, while both of its numerator and denominator, omega-6% and omega-3%, are negatively associated with mortality. Our findings support that both omega-6 and omega-3 PUFAs are protective against death and that the positive associations of the omega-6/omega-3 ratio with mortality outcomes are likely due to the stronger

17

effects of omega-3 than omega-6 PUFAs. Our mediation analysis with clinical biomarkers for
CVD and cancer revealed that CRP and SHBG partially medicated the effects of the omega6/omega-3 ratio on all-cause mortality. However, the proportions mediated are relatively small
(~5%), suggesting the presence of direct effects or unexamined factors. Our findings call for
future studies that evaluate the utility and investigate the mechanisms of the omega-6/omega-3
ratio.

412

413 Strengths of our current study include the use of objective PUFA biomarkers in plasma instead 414 of the estimated intakes from dietary questionnaires, which increases the accuracy of exposure 415 assessment. Moreover, the prospective population-based study design, large sample size, long 416 duration of follow-up, and detailed information on potential confounding variables, substantially 417 mitigate the possible complications from reverse causality and confounding bias. In several 418 sensitivity analyses, most of the documented associations remain materially unchanged, 419 indicating the robustness of our results.

420

421 Several potential limitations deserve attention. First, plasma omega-3 and omega-6 PUFAs were measured only once at baseline. Their levels may vary with diet or other lifestyle factors, which 422 423 could cause misclassification over follow-up. However, some studies demonstrated that multiple measurements of omega-3 PUFAs have been consistent for a 6-month period⁴⁵. Moreover, the 424 425 13-year within-person correlation for circulating omega-6 PUFAs was comparable to such correlations for other major CVD risk factors⁴⁶. Thus, the single measurement of PUFAs at 426 427 baseline, although not perfect, provides us with adequate information to investigate the relative 428 long-term effects. Second, although we adjusted for many potential confounders in the model,

429 we cannot rule out the imprecisely measured and unmeasured factors. Third, we acknowledged 430 that the cohort did not mirror the broader UK demographic in terms of socioeconomic and health 431 profiles. Participants in the UK Biobank generally exhibited better health and higher 432 socioeconomic status than the average UK resident, potentially influencing the disease 433 prevalence and incidence rates. Nonetheless, the UK Biobank's extensive sample size and 434 comprehensive exposure data enable the generation of valuable estimates for exposure-disease 435 associations. These estimates have been corroborated by findings from more demographically representative cohorts^{47,48}. Last, although we included individuals of different ancestries in the 436 analysis, over 90% of the participants were of European ancestry. The generalizability of our 437 findings across ancestries requires future verification. 438

439

440 **Conclusions**

441 In this large prospective cohort study, we documented robust positive associations of the plasma 442 omega-6/omega-3 fatty acids ratio with the risk of all-cause, cancer, and CVD mortality. Moreover, we found that plasma omega-3 and omega-6 PUFAs were independently and 443 444 inversely associated with the three mortality outcomes, with omega-3 fatty acids showing 445 stronger inverse associations. Our findings support the active management of a high circulating 446 level of omega-3 fatty acids and a low omega-6/omega-3 ratio to prevent premature death. 447 Future research is warranted to further test the causality, such as Mendelian randomization and 448 randomized controlled trials. Mechanistic research, including comprehensive mediation analysis, 449 in-depth experimental characterization in animal models or cell lines, and intervention studies, is 450 also needed to unravel the molecular and physiological underpinnings.

451

452 **Declarations**

453 Ethics approval and consent to participate

- 454 The UK Biobank received ethical approval from the research ethics committee (reference ID: 11/
- 455 NW/0382). Written informed consent was obtained from participants.

456 **Consent for publication**

457 Not applicable.

458 Availability of data and materials

459 The datasets analyzed during the current study are available from the UK Biobank through an

460 application process (www.ukbiobank.ac.uk/).

461 **Competing interests**

462 The authors declare no competing interests.

463 Funding

464 Research reported in this publication was supported by the National Institute of General Medical

465 Sciences of the National Institute of Health under the award number R35GM143060 (KY). The

466 content is solely the responsibility of the authors and does not necessarily represent the official

467 views of the National Institutes of Health.

468 Authors' contributions

- 469 YZ performed data analysis, prepared visualizations, and wrote the original draft of the
- 470 manuscript. YS, QY, and SS contributed to the data analysis. YS (yeshen@uga.edu) and KY
- 471 (kaixiong.ye@uga.edu) contributed equally to this project and should be considered co-
- 472 corresponding authors. They jointly designed and supervised the project. JTB contributed to the
- 473 interpretations of results. All authors critically edited the manuscript for important intellectual

- 474 content. The corresponding author (KY) attests that all listed authors meet the authorship criteria
- 475 and that no others meeting the criteria were omitted.

476 Acknowledgements

- 477 This research has been conducted using the UK Biobank Resource under Application Number
- 478 48818. We would like to express our heartfelt gratitude to the UK Biobank participants and
- 479 administrative staff.

480

481 Abbreviations

95% CI	95% confidence interval
ANOVA	Analysis of variance
BMI	Body mass index
CRP	C-creative protein
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
DHA%	Docosahexaenoic acid to total fatty acids percentage
E2	Oestradiol
EPA	Eicosapentaenoic acid
HR	Hazard ratio
LA	Linoleic acid
LA%	Linoleic acid to total fatty acids percentage
IGF-1	Insulin-like growth factor 1
Omega-3%	Omega-3 fatty acids to total fatty acids percentage
Omega-6%	Omega-6 fatty acids to total fatty acids percentage
PUFAs	Polyunsaturated fatty acids
Ref	Reference
SD	Standard deviation
SHBG	Sex hormone binding globulin
TTST	Testosterone

482

483

484

485

486 Supplementary Information

487 Additional file 1: Table S1. Literature review.

488 Additional file 2: Table S2. Risk estimates of ratio of plasma omega-6 to omega-3 PUFAs with

489 all-cause, cancer and CVD mortality, stratified by potential risk factors, in the UK Biobank

490 Study. Table S3. Associations of plasma omega-3 PUFAs percentage with all-cause, cancer, and

491 CVD mortality risk in the UK Biobank Study. Table S4. Associations of plasma omega-6

492 PUFAs percentage with all-cause, cancer, and CVD mortality risk in the UK Biobank Study.

Table S5. Fully adjusted joint associations of plasma omega-3 PUFAs percentage and omega-6

494 PUFAs percentage with all-cause and cause-specific mortality in the UK Biobank Study. Table

495 S6. Associations of the dietary PUFAs with all-cause, cancer, and CVD mortality risk in the UK

496 Biobank. Table S7. Selected participants serum biochemical markers at baseline across quintiles

497 of the plasma omega-6/omega-3 PUFAs ratio. **Table S8.** Mediation analysis of biomarkers on

498 associations between plasma omega-6/omega-3 ratio and mortality. Figure S1. Directed acyclic

499 graph to explain mediation. Table S9. Associations of DHA and LA with all-cause, cancer, and

500 CVD mortality risk in the UK Biobank. **Table S10.** Associations of ratio of omega-6/omega-3

501 PUFAs with all-cause, cancer, and CVD mortality risk in the UK Biobank, covariates including

502 fish oil supplementation status. Table S11. Associations of ratio of omega-6/omega-3 PUFAs

- 503 with all-cause, cancer, and CVD mortality risk in the UK Biobank Study, with multiple
- 504 imputation for missing data. **Table S12.** Associations of ratio of omega-6/omega-3 PUFAs with
- all-cause, cancer, and CVD mortality risk in the UK Biobank Study, excluding those who died in

- 506 the first follow-up year. Table S13. Baseline characteristics of participants with missing
- 507 exposure information and not included in the study.

508

- 509 **References**
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
 2019. Lancet. 2020;396(10258):1204-1222.
- 513 2. Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. *Curr Atheroscler* 514 *Rep.* 2009;11(6):411-417.
- 5153.Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary516heart disease? *Prev Med.* 2004;39(1):212-220.
- 5174.Harris WS, Luo J, Pottala JV, et al. Red blood cell polyunsaturated fatty acids and mortality518in the Women's Health Initiative Memory Study. J Clin Lipidol. 2017;11(1):250-259.e255.
- 5. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid
 levels are inversely associated with mortality and with incident cardiovascular disease: The
 Framingham Heart Study. *J Clin Lipidol.* 2018;12(3):718-727.e716.
- 522 6. Kleber ME, Delgado GE, Lorkowski S, März W, von Schacky C. Omega-3 fatty acids and
 523 mortality in patients referred for coronary angiography. The Ludwigshafen Risk and
 524 Cardiovascular Health Study. *Atherosclerosis.* 2016;252:175-181.
- 525 7. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for 526 Hypertriglyceridemia. *N Engl J Med.* 2019;380(1):11-22.
- 8. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil
 on major adverse cardiovascular events in patients at high cardiovascular risk: the
 STRENGTH randomized clinical trial. *JAMA*. 2020;324(22):2268-2280.
- 530 9. Delgado GE, März W, Lorkowski S, von Schacky C, Kleber ME. Omega-6 fatty acids:
 531 opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study. J
 532 *Clin Lipidol.* 2017;11(4):1082-1090.e1014.
- 53310.Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and534incident cardiovascular disease and mortality. *Circulation.* 2019;139(21):2422-2436.
- 53511.Wu JHY, Lemaitre RN, King IB, et al. Circulating omega-6 polyunsaturated fatty acids and536total and cause-specific mortality. *Circulation.* 2014;130(15):1245-1253.
- Harris K, Oshima M, Sattar N, et al. Plasma fatty acids and the risk of vascular disease and
 mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. *Diabetologia*. 2020;63(8):1637-1647.
- 540 13. Miura K, Hughes MCB, Ungerer JPJ, Green AC. Plasma eicosapentaenoic acid is negatively
 541 associated with all-cause mortality among men and women in a population-based
 542 prospective study. *Nutr Res.* 2016;36(11):1202-1209.
- 543 14. Otsuka R, Tange C, Nishita Y, et al. Fish and meat intake, serum eicosapentaenoic acid and
 544 docosahexaenoic acid levels, and mortality in community-dwelling Japanese older persons.
 545 Int J Environ Res Public Health. 2019;16(10).

Zhuang P, Wang W, Wang J, Zhang Y, Jiao J. Polyunsaturated fatty acids intake, omega-

6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. Clin Nutr.

546

547

15.

548		2019;38(2):848-855.
549	16.	Shim JS, Oh K, Kim HC. Dietary assessment methods in epidemiologic studies. <i>Epidemiol</i>
550		Health. 2014;36:e2014009.
551	17.	Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet.
552		2001;88:18-27.
553	18.	Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular
554		disease and other chronic diseases. Exp Biol Med. 2008;233(6):674-688.
555	19.	Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to
556		omega-3 intake, inflammation, and survival in long-term hemodialysis patients. Am J of
557		Kidney Dis. 2011;58(2):248-256.
558	20.	Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying
559		the causes of a wide range of complex diseases of middle and old age. PLOS Med.
560		2015;12(3):e1001779.
561	21.	Julkunen H, Cichońska A, Tiainen M, et al. Atlas of plasma NMR biomarkers for health and
562		disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023 Feb 3:14(1):604.
563		doi: 10.1038/s41467-023-36231-7.
564	22.	Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative
565		serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -
566		Omic technologies. Am J Epidemiol. 2017;186(9):1084-1096.
567	23.	Perez-Cornago A, Pollard Z, Young H, et al. Description of the updated nutrition calculation
568		of the Oxford WebQ questionnaire and comparison with the previous version among 207,144
569		participants in UK Biobank. Eur J Nutr. 2021;60(7):4019-4030.
570	24.	Chua ME, Sio MC, Sorongon MC, Dy JS. Relationship of dietary intake of omega-3 and
571		omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of
572		prospective studies and review of literature. Prostate Cancer. 2012;2012:826254.
573	25.	Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med.
574		1989;8(5):551-561.
575	26.	Li Z-H, Zhong W-F, Liu S, et al. Associations of habitual fish oil supplementation with
576		cardiovascular outcomes and all cause mortality: evidence from a large population based
577		cohort study. <i>BMJ.</i> 2020;368:m456.
578	27.	Zhang Y, Zhuang P, He W, et al. Association of fish and long-chain omega-3 fatty acids
579		intakes with total and cause-specific mortality: prospective analysis of 421 309 individuals. J
580		Intern Med. 2018;284(4):399-417.
581	28.	Lapointe-Shaw L, Bouck Z, Howell NA, et al. Mediation analysis with a time-to-event
582		outcome: a review of use and reporting in healthcare research. BMC Medical Research
583		Methodology. 2018;18(1):118.
584	29.	Valeri L, VanderWeele TJ. SAS Macro for Causal Mediation Analysis with Survival Data.
585		Epidemiology. 2015;26(2):e23-e24.
586	30.	VanderWeele TJ. Causal mediation analysis with survival data. <i>Epidemiology.</i>
587		2011;22(4):582-585.
588	31.	van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations
589		in R. J Stat Softw. 2011;45(3):1 - 67.
590	32.	Murff HJ, Tindle HA, Shrubsole MJ, et al. Smoking and red blood cell phospholipid
591		membrane fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2016;112:24-31.

- 592 33. Scaglia N, Chatkin J, Chapman KR, et al. The relationship between omega-3 and smoking
 593 habit: a cross-sectional study. *Lipids Health Dis.* 2016;15:61.
- Sequence 34. Chen GC, Yang J, Eggersdorfer M, Zhang W, Qin LQ. N-3 long-chain polyunsaturated fatty
 acids and risk of all-cause mortality among general populations: a meta-analysis. *Sci Rep.*2016;6:28165.
- 59735.Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and598cardiovascular risk markers in renal transplant recipients. *Eur J Clin Nutr.* 2016;70(7):824-599830.
- 60036.Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-601specific mortality from 17 prospective studies. Nat Commun. 2021;12(1):2329.
- 602 37. Lee S-H, Shin M-J, Kim J-S, et al. Blood eicosapentaenoic acid and docosahexaenoic acid
 603 as predictors of all-cause mortality in patients with acute myocardial infarction-data from
 604 Infarction Prognosis Study (IPS) Registry. *Circ J.* 2009;73(12):2250-2257.
- 605 38. Lindberg M, Saltvedt I, Sletvold O, Bjerve KS. Long-chain n-3 fatty acids and mortality in elderly patients. *Am J Clin Nutr.* 2008;88(3):722-729.
- 807 39. Pertiwi K, Küpers LK, Goede Jd, Zock PL, Kromhout D, Geleijnse JM. Dietary and circulating
 808 long-chain omega-3 polyunsaturated fatty acids and mortality risk after myocardial infarction:
 809 a long-term follow-up of the Alpha Omega Cohort. J Am Heart Assoc. 2021;10(23):e022617.
- 610 40. Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and
 611 docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart
 612 disease: the Heart and Soul study. *Circ Cardiovasc Qual Outcomes*. 2010;3(4):406-412.
- 613 41. Miura K, Hughes MCB, Ungerer JPJ, Smith DD, Green AC. Absolute versus relative
 614 measures of plasma fatty acids and health outcomes: example of phospholipid omega-3 and
 615 omega-6 fatty acids and all-cause mortality in women. *Eur J Nutr.* 2018;57(2):713-722.
- Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality
 and fatty acid desaturation as predictors of total and cardiovascular mortality: a populationbased prospective study. *Am J Clin Nutr.* 2008;88(1):203-209.
- 61943.de Lorgeril M, Renaud S, Salen P, et al. Mediterranean alpha-linolenic acid-rich diet in620secondary prevention of coronary heart disease. Lancet. 1994;343(8911):1454-1459.
- 62144.Petrone AB, Weir N, Hanson NQ, et al. Omega-6 fatty acids and risk of heart failure in the622Physicians' Health Study. Am J Clin Nutr. 2012;97(1):66-71.
- Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single
 measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in
 middle-aged Japanese men. *Eur J Clin Nutr.* 2001;55(8):643-650.
- 626 46. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to
 627 regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol.*628 1999;150(4):341-353.
- 629 47. Batty, G. D., Gale, C. R., Kivimäki, M., Deary, I. J., & Bell, S. Comparison of risk factor
 630 associations in UK Biobank against representative, general population based studies with
 631 conventional response rates: prospective cohort study and individual participant meta632 analysis. BMJ. 2020; 368: m131.
- 633 48. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE.
 634 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
 635 Participants With Those of the General Population. Am J Epidemiol. 2017;186(9):1026–34.

Tables

	Omega-6/omega-3 ratio quintiles								
Characteristics ^a	1 (median = 5.9) ($n = 17,085$)	2 (median = 7.6) (n = 17,085)	3 (median = 9.1) ($n = 17,085$)	4 (median = 11.0) (<i>n</i> = 17,085)	5 (median = 14.8) (n = 17,085)	Р			
Age (years)	58 6 (7 5)	57 2 (7 9)	55 7 (8 2)	547(83)	53 4 (8 2)	<0.001 ^b			
Sex (male%)	40.3	44 9	47 5	49.4	52.8	<0.001 ^c			
Ethnicity(n%)	1010	,		.,	0210	(01001			
White	15,375 (90,4%)	15.486 (91.0%)	15.494 (91.1%)	15.467 (91.1%)	15.420 (90.7%)	0.384°			
Black	113 (0.7%)	99 (0.6%)	105 (0.6%)	92 (0.5%)	116 (0.7%)				
Asian	673 (4.0%)	639 (3.8%)	663 (3.9%)	653 (3.8%)	659 (3.9%)				
Others	844 (5.0%)	786 (4.6%)	742 (4.4%)	773 (4.6%)	810 (4.8%)				
Missing (n)	80	75	81	100	80				
BMI	27.0 (4.4)	27.3 (4.5)	27.3 (4.7)	27.3 (4.8)	26.9 (5.0)	<0.001 ^b			
Missing (n)	54	64	55	58	71				
TDI	-1.6 (3.0)	-1.5 (3.0)	-1.4 (3.1)	-1.2 (3.1)	-0.9 (3.2)	<0.001 ^b			
Missing (n)	17	24	24	28	22				
Smoking status (n%)						< 0.001°			
Never	9,426 (55.5%)	9,272 (54.6%)	9,424 (55.4%)	9,400 (55.3%)	9,214 (54.2%)				
Previous	6,402 (37.7%)	6,194 (36.5%)	5,772 (34.0%)	5,492 (32.3%)	4,951 (29.1%)				
Current	1,162 (6.8%)	1,526 (9.0%)	1,802 (10.6%)	2,104 (12.4%)	2,832 (16.7%)				
Missing (n)	95	93	87	89	88				
Alcohol status (n%)						< 0.001°			
Never	631 (3.7%)	676 (4.0%)	655 (3.8%)	755 (4.4%)	974 (5.7%)				
Previous	536 (3.1%)	554 (3.2%)	535 (3.1%)	617 (3.6%)	835 (4.9%)				
Current	15,877 (93.2%)	15,822 (92.8%)	15,847 (93.0%)	15,664 (91.9%)	15,221 (89.4%)				
Missing (n)	41	33	48	49	55				
Physical activity (n%)						<0.001 ^c			
Low	2,422 (17.4%)	2,602 (18.8%)	2,653 (19.1%)	2,617 (19.0%)	2,613 (18.9%)				
Moderate	5,879 (42.2%)	5,762 (41.5%)	5,712 (41.1%)	5,533 (40.1%)	5,327 (38.6%)				
High	5,635 (40.4%)	5,506 (39.7%)	5,545 (39.9%)	5,654 (41.0%)	5,854 (42.4%)				
Missing (n)	3,149	3,215	3,175	3,281	3,291				

Table 1. Selected participants characteristics at baseline across quintiles of the plasma omega-6/omega-3 PUFAs ratio (n=85,425).

Fish oil supplementation (Yes%)	48.1	37.7	29.6	22.7	15.5	<0.001 ^c
Missing (n)	50	47	77	82	71	
Comorbidity (Yes%)	38.6	37.3	34.2	33.8	33.0	<0.001 ^c
Plasma omega-3 percentage	6.6 (1.4)	4.9 (0.5)	4.2 (0.4)	3.5 (0.3)	2.6 (0.5)	<0.001 ^b
Plasma omega-6 percentage	36.3 (3.7)	37.4 (3.4)	38.2 (3.3)	39.1 (3.2)	40.2 (3.1)	<0.001 ^b
Plasma DHA percentage	2.8 (0.8)	2.1 (0.5)	1.9 (0.4)	1.7 (0.4)	1.5 (0.4)	<0.001 ^b
Plasma LA percentage	27.0 (3.3)	28.4 (3.1)	29.3 (3.0)	30.2 (3.0)	31.3 (3.1)	<0.001 ^b
Dietary omega-3 percentage	3.6 (1.8)	3.2 (1.4)	3.0 (1.3)	2.9 (1.2)	2.7 (1.0)	<0.001 ^b
Missing (n)	9,355	9,628	9,857	9,974	10,288	
Dietary omaga-6 percentage	16.8 (4.6)	16.5 (4.4)	16.6 (4.6)	16.5 (4.7)	16.5 (4.8)	<0.001 ^b
Missing (n)	9,355	9,628	9,857	9,974	10,288	

^a All variables measured at baseline are presented as mean (SD) unless otherwise specified.

^b From the ANOVA test for continuous variables.

^c From the Pearson's Chi-squared test for categorical variables.

	Causes of death										
Omaga	All-cause				Cancer		Cardiovascular diseases				
ratio variable forms	Number of deaths	Partially adjusted associations ^b	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b HR	Fully adjusted associations ^c	Number of deaths	Partially adjusted associations ^b HR	Fully adjusted associations ^c		
		HR	HR			HR			HR		
		(95% CI)	(95% CI)		(95% CI)	(95% CI)		(95% CI)	(95% CI)		
Continuous	6,461	1.02 (1.02-1.03)	1.02 (1.02-1.03)	2,794	1.02 (1.01-1.03)	1.01 (1.00-1.02)	1,668	1.02 (1.01-1.03)	1.02 (1.01-1.03)		
Quintiles (median)											
1 (5.9)	1,348	1.00 (ref)	1.00 (ref)	593	1.00 (ref)	1.00 (ref)	369	1.00 (ref)	1.00 (ref)		
2 (7.6)	1,256	1.00 (0.92-1.08)	0.96 (0.88-1.05)	563	1.02 (0.91-1.15)	0.98 (0.86-1.12)	315	0.90 (0.77-1.05)	0.89 (0.75-1.06)		
3 (9.1)	1,236	1.06 (0.98-1.15)	1.01 (0.93-1.11)	543	1.08 (0.96-1.21)	0.99 (0.87-1.13)	321	0.97 (0.84-1.13)	0.97 (0.81-1.16)		
4 (11.0)	1,252	1.14 (1.06-1.23)	1.09 (1.00-1.19)	548	1.16 (1.03-1.31)	1.12 (0.98-1.27)	306	0.98 (0.84-1.15)	1.02 (0.86-1.22)		
5 (14.8)	1,369	1.34 (1.24-1.45)	1.26 (1.15-1.38)	547	1.27 (1.12-1.43)	1.14 (1.00-1.31)	357	1.20 (1.04-1.40)	1.31 (1.10-1.55)		
P_{trend}		<0.001	<0.001		<0.001	0.011		0.002	<0.001		

Table 2. Associations^a of the plasma omega-6/omega-3 PUFAs ratio with all-cause, cancer, and CVD mortality risk in the UK Biobank.

Abbreviations: CI, confidence interval; HR, hazards ratio; ref, reference.

^a From Cox proportional hazards regression.

^b Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre.

^c Adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m2; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure Legends

Figure 1. Risk estimates of all-cause mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m2; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 2. Risk estimates of cause-specific mortality for the highest compared with the lowest quintile of the ratio of plasma omega-6 to omega-3 PUFAs, stratified by potential risk factors. Results were adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m2; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Figure 3. Associations of the ratio of omega-6/omega-3 PUFAs with all-cause and cause-specific mortality evaluated using restricted cubic splines. Hazard ratios and omega ratios are presented in the vertical and horizontal axis, respectively. The best estimates and their confidence intervals are presented as solid red lines and dotted black lines, respectively. The ratio 4 was selected as a reference level, and the x-axis depicts the ratio from 0 to 40. Potential nonlinearity was identified for all-cause mortality (p < 0.05) and CVD-caused mortality (p < 0.05), but not for cancer-caused mortality (p = 0.12). All HRs are adjusted for age (years; continuous), sex (male, female), race (White, Black, Asian, Others), Townsend deprivation index (continuous), assessment centre, BMI (kg/m2; continuous), smoking status (never, previous, current), alcohol intake status (never, previous, current), physical activity (low, moderate, high), and comorbidities (yes, no).

Subgroup	No. of Participants	No. of Death (%)		Hazard Ratio (95% CI)	P value for interaction
Overall	17,085	1,369 (8.01)	┝╌┳╌┤	1.26 (1.15-1.38)	h was n
Age (years) < 58 >= 58	11,146 5,939	430 (3.86) 939 (15.81)	─── ─┤ ├─ ■ ─┤	1.11 (0.91-1.34) 1.17 (1.06-1.29)	0.8 0.8
Sex Male Female	9,020 8,065	980 (10.86) 389 (4.82)	├ ─── ┤ ├─── ─ ──┤	1.29 (1.16-1.44) 1.22 (1.04-1.42)	0.8 0.8 0.8
TDI < -2 >= -2	7,823 9,240	500 (6.39) 868 (9.39)	┝──╋──┤ ┝──╋──┤	1.17 (1.02-1.33) 1.38 (1.22-1.55)	0.27 0.27 0.27
BMI (kg/m²) < 25 >= 25	6,673 10,341	429 (6.43) 927 (8.96)	⊦i	1.15 (0.97-1.36) 1.30 (1.17-1.44)	0.6 0.6
Comorbidity Yes No	5,639 11,446	849 (15.06) 520 (4.54)	} ∎ ∎	1.27 (1.14-1.42) 1.24 (1.07-1.43)	0.22 0.22
Physical Activity Low or Moderate High	7,940 5,854	651 (8.2) 383 (6.54)	├ ── ──┤ ├── ─ ──┤	1.30 (1.17-1.46) 1.20 (1.04-1.39)	0.88 0.88
Current Smoking Status Yes No	2,832 14,165	438 (15.47) 918 (6.48)		1.57 (1.26-1.95) 1.18 (1.06-1.30)	< 0.01 < 0.01

			Cancer Mortality				CVD Mortality		rtifie
Subgroup	No. of Participants	No. of Death (%)		Hazard Ratio (95% CI)	P value for interaction	No. of Death (%)		Hazard Ratio (95% CI)	P value for interaction
Overall	17,085	547 (3.2)	╞─■─┤	1.14 (1.00-1.31)		357 (2.09)	┝╼╌┤	1.31 (1.10-1.55)	r rev
Age (years) < 58 >= 58	11,146 5,939	188 (1.69) - H 359 (6.04)		1.07 (0.80-1.43) 1.04 (0.89-1.21)	0.85	112 (1) 245 (4.13)	┝╼╌┤	1.11 (0.77-1.61) 1.24 (1.02-1.51)	s gade avai
Sex Male Female	9,020 8,065	355 (3.94) 192 (2.38)		1.17 (0.98-1.40) 1.11 (0.89-1.38)	0.33	282 (3.13) 75 (0.93)	┝╼╌┤	1.31 (1.08-1.60) 1.31 (0.91-1.88)	0.73ble und
TDI < -2 >= -2	7,823 9,240	240 (3.07) 307 (3.32)		1.06 (0.88-1.28) 1.29 (1.06-1.58)	0.4	121 (1.55) 235 (2.54)		1.35 (1.04-1.75) 1.32 (1.05-1.66)	der, who ha 0.8 CC-BY 0.8 CC-BY
BMI (kg/m ²) < 25 >= 25	6,673 10,341	184 (2.76) 362 (3.5)		1.04 (0.81-1.34) 1.19 (1.01-1.40)	0.78	97 (1.45) 257 (2.49)		1.32 (0.93-1.88) 1.30 (1.07-1.59)	0.620 4.0 In
Comorbidity Yes No	5,639 11,446	282 (5) 265 (2.32)		1.12 (0.93-1.35) 1.17 (0.96-1.43)	0.74	250 (4.43) 107 (0.93)	┝╼╌┤	1.24 (1.01-1.52) 1.47 (1.05-2.06)	<0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04 <0.04
Physical Activity Low or Moderate High	7,940 5,854	247 (3.11) 165 (2.82)		1.17 (0.98-1.39) 1.11 (0.89-1.38)	0.99	180 (2.27) 100 (1.71)	- ■ - ■	1.37 (1.10-1.70) 1.22 (0.91-1.62)	0.19 0.19 Sense to
Current Smoking Status Yes No	2,832 14,165	176 (6.21) 367 (2.59)		1.41 (1.01-1.97) 1.06 (0.91-1.23) 2	0.13	116 (4.1) 238 (1.68)		2.09 (1.33-3.27) 1.18 (0.97-1.43) .5	0.12 display the pr

0 -

All-cause Mortality

Cancer Mortality

CVD Mortality



Ratio of omega-6/omega-3 PUFAs

Ratio of omega-6/omega-3 PUFAs

Ratio of omega-6/omega-3 PUFAs